



Universiteit
Leiden
The Netherlands

ADP-ribose analogues: synthetic strategy towards inhibitors for viral macrodomains: SARS-CoV-2

Rijpkema, K.J.

Citation

Rijpkema, K. J. (2026, April 16). *ADP-ribose analogues: synthetic strategy towards inhibitors for viral macrodomains: SARS-CoV-2*. Retrieved from <https://hdl.handle.net/1887/4302122>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4302122>

Note: To cite this publication please use the final published version (if applicable).




Since the global COVID-19 pandemic, the coronavirus responsible (SARS-CoV-2) has been extensively probed for promising protein targets to establish drug-based therapies. One of these protein targets, the macrodomain known as Mac1, binds the post-translational modification adenosine-diphosphate-ribose (ADP-ribose) and removes it from important immunological signalling molecules. This process, critical for the propagation of the virus, can be inhibited by introducing a molecule that binds better to Mac1 than the ADP-ribose, namely, an ADP-ribose analogue.

In his thesis titled **ADP-ribose analogues** the author Koen J. Rijpkema explores the different facets of the ADP-ribose molecule and the way that structurally changing these facets through synthetic organic chemistry has an influence on the binding affinity of the analogues for Mac1.



ADP-ribose analogues

by Koen Rijpkema



ADP-ribose analogues

by Koen Rijpkema

Chemical structure of ADP-ribose and a 'To Do' list.

Chemical structure: CC(=O)O[C@@H]1O[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@H](O)[C@@H](O)[C@H]1O

To Do:

- 4hr
- 4hr
- 2hr
- 1hr
- 1hr